AOD-9604 long term side effects: what the human trials actually show

Last updated 2026-07-25

What is AOD-9604 and why did anyone think it would work?

AOD-9604 is a synthetic fragment of human growth hormone, built from the C-terminal 176-191 region of the hGH molecule. The idea behind it, going back to research in Australia in the early 2000s, was to isolate the piece of hGH responsible for fat metabolism while dropping the growth-promoting effects that make full-length hGH risky and tightly controlled. That's the whole pitch: a fragment that supposedly triggers lipolysis (fat breakdown) and blocks lipogenesis (fat storage) without pushing IGF-1 up or causing the joint swelling, insulin resistance, and organ growth associated with growth hormone excess. A 2004 review in Current Opinion in Investigational Drugs describes AOD-9604 specifically as a metabolic fragment being developed on this fat-targeting rationale ^[1]. It's a reasonable hypothesis on paper. The problem is what happened when it got tested in actual humans, not what happened in the biochemistry lab or in rodent models.

What did the human obesity trials actually find?

AOD-9604 went through Phase II human obesity trials, and this is the part that gets glossed over in most marketing copy. The trials didn't show a weight-loss effect that clearly beat placebo. The published trial reporting on this program, cataloged under the 'Gateways to clinical trials' series in Methods and Findings in Experimental and Clinical Pharmacology, tracked AOD-9604 through its obesity development pipeline across multiple entries in 2003 and 2005 ^[2][3][4]. A separate 2006 review of the obesity drug pipeline in Current Opinion in Investigational Drugs places AOD-9604 among the compounds that failed to produce a difference from placebo strong enough to justify further development for weight loss ^[5]. This is the central fact anyone researching this peptide needs to sit with: the human data that exists does not support meaningful fat loss over placebo. Any long-term safety picture has to be read against that backdrop, because a drug that never showed it works isn't a drug anyone ran multi-year trials on to check what happens if you keep taking it. If you're comparing this against therapies with a firmer weight-loss signal, our AOD-9604 vs tesamorelin comparison lays out the evidence gap side by side.

Is there any long-term human safety data on AOD-9604?

No. That's the honest, short answer. The published record on AOD-9604 is dominated by early-phase pharmacology, isolated analytical chemistry papers, and drug-testing detection studies, not multi-year outcome tracking. Nothing in the available literature follows a human cohort taking AOD-9604 for a year or more and reports on organ function, metabolic markers, or adverse events over that timeframe. What we do have are Phase II obesity trial reports from the mid-2000s ^[2][3][4], a 2004 metabolic mechanism review ^[1], and a 2013 paper confirming AOD-9604 doesn't trigger a false positive on the WADA hGH isoform immunoassay ^[6], which tells you something about its molecular behavior in anti-doping testing but nothing about safety over time. More recent literature (a 2026 orthopaedic peptide review and a 2026 sports medicine review of unapproved peptide therapies) covers AOD-9604 in the broader context of musculoskeletal and performance peptide use, but these are reviews synthesizing what's known, not new long-term trial data generating fresh safety numbers ^[7][8]. If you're weighing this against the underlying AOD-9604 peptide evidence base generally, that gap in long-term follow-up is the single biggest thing to know going in.

What side effects were reported in the short-term trials?

The published trial record for AOD-9604 is thin on granular adverse-event tables you can quote line by line. What's consistently reported across the fragment's rationale and trial write-ups is the absence of the growth-hormone-linked side effects seen with full-length hGH, things like joint pain, fluid retention, and elevated IGF-1 ^[1]. That's a meaningful distinction on the mechanism side. AOD-9604 was specifically engineered to not raise IGF-1 or trigger the tissue-growth signaling that makes hGH itself a regulated, prescription-only hormone with a known long-term risk profile. But 'we didn't see the hGH-specific side effects in short trials' is a different claim from 'this is safe long-term.' Short Phase II trials aren't built to catch rare or slow-accumulating effects. Injection site reactions, which are common to essentially any subcutaneous peptide product, aren't well quantified in the AOD-9604 literature specifically. Anyone using compounded product should also weigh the sourcing and quality-control layer separately from the biology, since that introduces its own risk that has nothing to do with the fragment's actual pharmacology.

Does AOD-9604 raise IGF-1 or affect growth hormone levels?

The rationale behind AOD-9604 was to strip out the part of the hGH molecule responsible for IGF-1 elevation and growth signaling, keeping only the fragment linked to lipid metabolism ^[1]. That's the theoretical selling point over using full hGH off-label for fat loss. The 2013 Drug Testing and Analysis study is useful here for a different reason: it confirmed AOD-9604 doesn't interfere with the WADA hGH isoform immunoassay, the test anti-doping labs use to detect exogenous growth hormone ^[6]. That finding matters for athletes and testing contexts, but it's a molecular/analytical result, not a clinical statement about IGF-1 levels or long-term hormone effects in patients taking AOD-9604 for fat loss. Nobody has published a long-term human study tracking IGF-1 over months or years of AOD-9604 use at fat-loss doses. If someone tells you IGF-1 stays flat over a year of use, that's not backed by a published cohort, it's an extrapolation from the fragment's design intent.

Are there any organ, metabolic, or cardiovascular risks with long-term use?

There's no published long-term data to answer this directly, which is itself the answer worth internalizing. No study in the AOD-9604 literature tracks liver enzymes, kidney function, lipid panels, or cardiovascular markers over an extended period of use. The Phase II obesity trials that exist ran on the timescale typical of early drug development, weeks to a few months, not years ^[2][3][4]. A 2006 review of the obesity drug development pipeline that includes AOD-9604 discusses it in the context of compounds that didn't advance past this stage due to lack of efficacy separation from placebo ^[5], which also means it didn't advance into the larger, longer Phase III trials that would normally generate a real long-term safety dataset. This is a structural point, not a scare tactic: drugs that show no efficacy signal in Phase II typically don't get funded into Phase III, and Phase III is where you'd normally get the multi-year, multi-thousand-patient safety data regulators actually rely on. AOD-9604 stalled before that stage, on the record we have.

Is AOD-9604 FDA-approved, and what does that mean for safety oversight?

No. AOD-9604 has no FDA-approved product listing. You can check this yourself in Drugs@FDA, the FDA's database of approved drug products ^[9], and you won't find an AOD-9604 entry there. That absence matters for long-term safety specifically because FDA approval is what normally comes bundled with post-market surveillance requirements, standardized manufacturing controls, and a formal adverse-event reporting pipeline (like FAERS) that catches rare, delayed, or long-term problems after a drug reaches wide use. Without approval, none of that infrastructure exists for AOD-9604. AOD-9604 also isn't on FDA's 503A bulk drug substances list for compounding ^[10] or the 503B list for outsourcing facilities ^[11], the two lists that let compounding pharmacies legally use a bulk substance in patient-specific or office-use preparations under 21 U.S.C. 353a ^[12]. FDA's nomination list for substances under review for 503A inclusion is a separate, evolving document ^[13], and status there can change, so check it directly rather than relying on secondhand summaries. Practically, this means AOD-9604 sold in the US sits in a gray or research-use-only space, and any product marketed for human use outside that framework is operating outside FDA's intended-use rules under 21 CFR 201.128 ^[14].

How does AOD-9604's safety picture compare to other fat-loss peptides?

This is where it helps to zoom out. AOD-9604 isn't unique in being a peptide with a thin long-term human safety record, but it is unusual in having a fairly clear negative efficacy signal from the trials that were run.

The honest takeaway from this table: AOD-9604 is the only one of the three where the human obesity trial itself didn't show a clean win. That's a different category of uncertainty than 'not enough long-term data yet' for a drug that at least demonstrated it works. For a full breakdown of how the fragment stacks up against a peptide with an actual approved indication, see AOD-9604 vs tesamorelin.

Can long-term AOD-9604 use be detected in drug testing?

Yes, and the detection science here is actually more developed than the safety science. Multiple analytical chemistry papers cover methods for picking up AOD-9604 and similar peptide fragments in doping control samples. A 2014 review in Journal of Pharmaceutical and Biomedical Analysis covers analytical approaches for detecting emerging therapeutics and non-approved drugs, including small peptides like AOD-9604, in human doping controls ^[15]. A companion 2014 review in Expert Review of Proteomics covers detection strategies for peptidic drugs, drug candidates, and analogs specifically in the sports doping context ^[16]. A 2016 paper in Journal of Separation Science describes a method using direct urine injection with liquid chromatography and ion mobility mass spectrometry to screen for peptides under 2 kDa, a category that includes fragments like AOD-9604 ^[17]. AOD-9604 itself doesn't interfere with the standard WADA hGH isoform immunoassay ^[6], but it is still a substance that shows up on prohibited lists and dedicated detection methods exist for it. If you're an athlete under testing, this is relevant regardless of what you conclude about the fat-loss efficacy question.

What are the injection-related and practical safety concerns?

Setting the efficacy debate aside for a moment, anyone injecting any peptide subcutaneously takes on a baseline set of practical risks that have nothing to do with the specific molecule. Injection site reactions (redness, swelling, minor bruising) are common across this category of product. Sterility of reconstitution matters enormously, since improperly reconstituted or contaminated product introduces infection risk independent of anything the peptide itself does. See our guide on how to reconstitute AOD-9604 for the mechanics of doing this safely if you've already decided to proceed. A separate and arguably bigger practical risk is sourcing. Because AOD-9604 isn't FDA-approved and isn't on the compounding bulks lists ^[10][11], product sold for human use often comes through channels with no standardized purity or dosing verification. That's a supply-chain risk layered on top of, not instead of, the underlying efficacy and long-term-safety uncertainty. If you're going to source at all, going through a provider-reviewed route with pharmacy-level fulfillment reduces (though doesn't eliminate) that layer of risk relative to unverified retail sellers.

Who should avoid AOD-9604 entirely, and what's a more evidence-backed alternative?

Given everything above, a few groups should think especially hard before using AOD-9604: anyone pregnant or breastfeeding, anyone with active cancer or a history of hormone-sensitive tumors (given the hGH-derived origin, even if the fragment is designed to avoid growth signaling), and anyone under active drug testing in a sport where it's prohibited. More broadly, anyone who wants a fat-loss intervention backed by trials that actually showed a placebo-beating effect should look elsewhere first. Tesamorelin has an FDA-approved indication (for HIV-associated lipodystrophy specifically, not general obesity) and a real post-approval track record. Established, boring interventions, caloric deficit, resistance training, GLP-1 medications with large randomized trial data behind them, all have a stronger evidence base for actual fat loss than AOD-9604 has ever produced in a human trial. AOD-9604 Co's position on this is straightforward: the fragment rationale is real biochemistry and the mechanism paper is legitimate ^[1], but the human obesity trials that tested the actual weight-loss promise didn't deliver a result that separated from placebo ^[5]. That's not a reason to panic if you've used it, but it is a reason to keep expectations calibrated and to treat any long-term safety claims you hear as unproven rather than reassuring.

What should you ask a provider before starting AOD-9604?

If you're going to explore AOD-9604 despite the efficacy gap, the questions worth asking are less about hype and more about basic due diligence. Ask where the product is compounded and whether that pharmacy provides third-party purity testing. Ask what the reconstituted product's stability and storage requirements are, since improper handling changes the risk profile. Ask whether the provider tracks and discloses adverse event reports from other patients, even informally. Ask directly: 'what does the human trial evidence say about whether this works for fat loss?' A provider who answers that honestly, citing the Phase II trial gap ^[2][3][4][5] rather than glossing over it, is a better sign than one who leads with testimonials. Our page on when to take AOD-9604 peptide covers the practical timing questions if you've already decided to proceed under provider guidance. The bar here should be the same one you'd apply to any unapproved compound: does the person selling it to you understand and disclose what the actual trial record shows, or are they selling you the mechanism story without the outcome data attached.

Frequently asked questions

Does AOD-9604 have any known long-term side effects in humans?

No published study tracks AOD-9604 use over multiple years, so there's no documented long-term side effect profile. Short Phase II obesity trials didn't report the classic hGH-linked issues like joint pain or fluid retention ^[1], but that's a short-term finding, not a long-term safety guarantee.

Did AOD-9604 actually work for weight loss in human trials?

The published trial record shows AOD-9604's Phase II obesity trials did not produce a weight-loss effect that clearly separated from placebo ^[2][3][4][5]. This is the central limitation anyone considering it should understand before anything else.

Is AOD-9604 FDA-approved?

No. There's no AOD-9604 listing in Drugs@FDA, the FDA's approved drug products database ^[9]. It's also not on FDA's 503A or 503B bulk drug substance lists used for legal compounding ^[10][11].

Does AOD-9604 raise IGF-1 like full-length HGH does?

The fragment was specifically designed to exclude the part of hGH linked to IGF-1 elevation and growth signaling ^[1]. No long-term human study has measured IGF-1 levels over extended AOD-9604 use, so this remains a design intent rather than a confirmed clinical outcome.

Can AOD-9604 be detected in a drug test?

Yes. Analytical methods for detecting peptides like AOD-9604 in doping controls are documented in multiple papers, including a 2016 method using direct urine injection with liquid chromatography and ion mobility mass spectrometry ^[17]. Separately, AOD-9604 doesn't trigger false positives on the WADA hGH isoform immunoassay ^[6].

What's the difference between AOD-9604 and tesamorelin for safety data?

Tesamorelin has an FDA-approved indication and a genuine post-approval surveillance record. AOD-9604 never advanced past Phase II obesity trials due to a lack of efficacy separation from placebo ^[5], so it has no comparable long-term dataset. See AOD-9604 vs tesamorelin for the full comparison.

Is it legal to buy AOD-9604 in the US?

AOD-9604 isn't on FDA's 503A bulks list ^[10] or 503B bulks list ^[11], the lists that authorize compounding pharmacies to use a bulk substance under 21 U.S.C. 353a ^[12]. That leaves most human-use sales in a gray or unapproved-use zone; check current FDA nomination status directly ^[13] before assuming anything has changed.

What side effects have been reported in AOD-9604 trials?

Published trial write-ups don't include detailed adverse-event tables readily available in the general literature. What's reported is the absence of hGH-typical effects like joint swelling and elevated IGF-1 ^[1], but this comes from short trials, not extended use monitoring.

Does AOD-9604 cause insulin resistance long term?

There's no published long-term human data addressing this specifically. Full-length hGH is known to affect insulin sensitivity, but AOD-9604 was engineered to exclude that growth-hormone activity ^[1]. Without a long-term trial, this remains unverified either way.

Why didn't AOD-9604 get FDA approval?

Its Phase II obesity trials didn't show a weight-loss effect that separated clearly from placebo, a finding covered in a 2006 review of the obesity drug development pipeline ^[5]. Drugs generally don't advance to the larger Phase III trials needed for approval without a positive Phase II signal.

Is AOD-9604 safer than regular HGH for fat loss?

On paper, yes, in that it was designed to avoid IGF-1 elevation and growth-signaling side effects tied to full hGH ^[1]. But 'designed to avoid' isn't the same as 'proven safe long-term'; no extended human safety study exists for AOD-9604 to confirm this holds up over years of use.

Where can I read the actual AOD-9604 obesity trial results?

The Phase II obesity trial program is documented across entries in the 'Gateways to clinical trials' series in Methods and Findings in Experimental and Clinical Pharmacology (2003 and 2005) ^[2][3][4], and summarized in a 2006 obesity drug pipeline review ^[5].

Sources

1. Current Opinion in Investigational Drugs, 2004 (PMID 15134286): AOD-9604 is described as a metabolic fragment of hGH developed on a fat-metabolism rationale distinct from growth-promoting effects.
2. Methods and Findings in Experimental and Clinical Pharmacology, 2003 (PMID 14685303): Documents AOD-9604's Phase II obesity clinical trial development pipeline entry.
3. Methods and Findings in Experimental and Clinical Pharmacology, 2003 (PMID 14571286): Documents AOD-9604's Phase II obesity clinical trial development pipeline entry.
4. Methods and Findings in Experimental and Clinical Pharmacology, 2005 (PMID 15834452): Documents continued tracking of AOD-9604 through the obesity clinical trial gateway pipeline into 2005.
5. Current Opinion in Investigational Drugs, 2006 (PMID 16625817): Reviews the obesity drug development pipeline and places AOD-9604 among compounds that did not show weight-loss separation from placebo strong enough to advance further.
6. Drug Testing and Analysis, 2013 (PMID 24124033): Confirms AOD-9604 does not influence or cause false positives on the WADA hGH isoform immunoassay.
7. Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptides including AOD-9604 in orthopaedic applications, covering current evidence and challenges.
8. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, including AOD-9604.
9. FDA, Drugs@FDA database: AOD-9604 has no FDA-approved drug product listing; used to verify approval status of comparator drugs.
10. 21 CFR 216.23, the 503A Bulks List: AOD-9604 is not included on the FDA 503A bulk drug substances list authorized for compounding.
11. 21 CFR 216.24, the 503B Bulks List: AOD-9604 is not included on the FDA 503B bulk drug substances list for outsourcing facilities.
12. 21 U.S.C. 353a, pharmacy compounding: Establishes the legal framework under which compounding pharmacies may use bulk drug substances for patient-specific preparations.
13. FDA, bulk drug substances nominated for use in compounding (current list): Lists substances currently nominated and under FDA review for potential 503A bulks list inclusion, a status subject to change.
14. 21 CFR 201.128, meaning of intended uses: Defines the regulatory concept of intended use that governs marketing claims for unapproved substances like AOD-9604.
15. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Reviews analytical approaches for detecting emerging therapeutics and non-approved drugs, including small peptides, in human doping controls.
16. Expert Review of Proteomics, 2014 (PMID 25382550): Reviews detection strategies for peptidic drugs, drug candidates, and analogs in sports doping contexts.
17. Journal of Separation Science, 2016 (PMID 26578461): Describes a direct urine injection LC/ion mobility mass spectrometry method for screening peptides under 2 kDa, a category including AOD-9604.